The Safety of Rosuvastatin as Used in Common Clinical Practice | Zendy

Alawi AlsheikhAli | Zendy; Marietta S. Ambrose | Zendy; Jeffrey T. Kuvin | Zendy; Richard H. Karas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Safety of Rosuvastatin as Used in Common Clinical Practice

Author(s) -

Alawi AlsheikhAli,

Marietta S. Ambrose,

Jeffrey T. Kuvin,

Richard H. Karas

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.555482

Subject(s) - rosuvastatin , medicine , rhabdomyolysis , pravastatin , cerivastatin , simvastatin , statin , adverse effect , dyslipidemia , atorvastatin , adverse event reporting system , proteinuria , pharmacology , disease , cholesterol , kidney

Statins are currently the mainstay of dyslipidemia management for the primary and secondary prevention of cardiovascular disease. Controversial concerns about the safety of the newly marketed statin rosuvastatin have been raised on the basis of premarketing studies and a few postmarketing reports.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research